AI blood testing technology developed to detect lung cancers

A research team from Johns Hopkins Kimmel Cancer Center found that the AI blood testing solution was able to detect over 90% of lung cancers in samples from nearly 800 individuals with and without cancer. The research findings have been published in Nature Communications. Known as DELFI (DNA evaluation of fragments for early interception), the test is designed to detect unique patterns in the fragmentation of DNA shed from cancer cells circulating in the bloodstream. Researchers applied the DELFI technology to blood samples taken from 796 individuals in Denmark, the Netherlands, and the USA. They determined that the DELFI approach accurately distinguished between patients with and without lung cancer.